Stem cell consortium tackles complex genetic diseases

April 06, 2017

Much of stem cell research over the past decade has focused on Mendelian disorders -- those caused by a single gene, such as cystic fibrosis, muscular dystrophy, and Huntington's disease. But as genome-wide association studies continue to reveal, most conditions are more complex, arising from dozens or hundreds of genetic mutations working together to cause disease. To understand how someone can inherit a higher risk for hypertension or diabetes, it's necessary to study how these mutations contribute on a cellular level.

To address this challenge, in 2010, the US National Heart, Lung, and Blood Institute's (NHLBI) Next Generation Genetic Association Studies Consortium sponsored a series of studies that began the hard work of analyzing induced pluripotent stem (iPS) cells gathered from large groups of patients to learn more about how individual mutations contribute to polygenetic diseases. Now, a group of 11 reports resulting from the collaborative effort appear in Cell Stem Cell, Stem Cell Reports, and EBioMedicine. The papers are presented on an interactive web portal, http://www.cell.com/consortium/NextGen.

"When this started, the stem cell field had begun to get to the point where you could contemplate making iPS cells at scale for perhaps hundreds or thousands of individuals," says Chad Cowan of the Harvard Stem Cell Institute, Massachusetts General Hospital, and the Broad Institute. "The time was right and the NHLBI had the vision to know that the next step in genome-wide association studies is to systematically interrogate the molecular mechanisms of specific genes with in iPS cells."

The challenge the consortium aimed to overcome was: if a condition--such as cardiovascular disease -- has over 100 mutations that could contribute to its cause, how do you measure each gene's role? Animal models are unlikely to help because the changes may be too subtle, and studying stem cell lines from one individual wouldn't tell the whole story as people carry different genetic risk factors. So, the research groups generated iPS cell lines -- each requiring around 4-6 months of labor and costing up to $20,000--from hundreds of individuals to assess the physiological variation.

This resource is already yielding several lessons: one, the number of stem cell lines needed to analyze polygenetic disease may not require hundreds of samples. Cowan, who looked at liver metabolism abnormalities, found that his group could get results with a smaller collection of cells. Two, very small changes in gene expression could yield surprisingly dramatic changes in a cell, and researchers are curious to find out how. Three, some of the effects mutations have on cells may manifest before the stem cells are differentiated.

"While iPSCs show considerable promise as a complement to genome-wide association studies in understanding the functional basis of variation, there is still quite a lot of work to do in terms of standardization of protocols and understanding of best practices to make this type of approach a reliable discovery tool," writes Cell Stem Cell Editor Deborah Sweet in an editorial about the consortium (DOI: 10.1016/j.stem.2017.03.020). "The potential is there, though, and it's an exciting prospect to consider."

The work will also be helpful to establish the fundamental building blocks for studying polygenetic diseases. For example, these cell lines are something researchers can order from a distributor (WiCell) in the near future. The efforts may also lead to more targeted therapeutics. Other large-scale research efforts with goals similar to those of the NextGen Consortium are also in progress. In Europe, there is the HipSci Initiative in the UK and the EU project StemBANCC.
-end-
The NextGen Consortium Reports:

Cell Stem Cell, Warren et al.: "The Next Generation Genetic Association Studies Consortium Lights the Way: In Vitro Genetics Made Possible by iPSCs" http://www.cell.com/cell-stem-cell/fulltext/S1934-5909(17)30092-9

Cell Stem Cell (@CellStemCell), published by Cell Press, is a monthly journal that publishes research reports describing novel results of unusual significance in all areas of stem cell research. Each issue also contains a wide variety of review and analysis articles covering topics relevant to stem cell research ranging from basic biological advances to ethical, policy, and funding issues. Visit: http://www.cell.com/cell-stem-cell. To receive Cell Press media alerts, contact press@cell.com.

Cell Press

Related Muscular Dystrophy Articles from Brightsurf:

Using CRISPR to find muscular dystrophy treatments
A study from Boston Children's Hospital used CRISPR-Cas9 to better understand facioscapulohumeral muscular dystrophy (FSHD) and explore potential treatments by systematically deleting every gene in the genome.

Duchenne muscular dystrophy diagnosis improved by simple accelerometers
Testing for Duchenne muscular dystrophy can require specialized equipment, invasive procedures and high expense, but measuring changes in muscle function and identifying compensatory walking gait could lead to earlier detection.

New therapy targets cause of adult-onset muscular dystrophy
The compound designed at Scripps Research, called Cugamycin, works by recognizing toxic RNA repeats and destroying the garbled gene transcript.

Gene therapy cassettes improved for muscular dystrophy
Experimental gene therapy cassettes for Duchenne muscular dystrophy have been modified to deliver better performance.

Discovery points to innovative new way to treat Duchenne muscular dystrophy
Researchers at The Ottawa Hospital and the University of Ottawa have discovered a new way to treat the loss of muscle function caused by Duchenne muscular dystrophy in animal models of the disease.

Extracellular RNA in urine may provide useful biomarkers for muscular dystrophy
Massachusetts General Hospital researchers have found that extracellular RNA in urine may be a source of biomarkers for the two most common forms of muscular dystrophy, noninvasively providing information about whether therapeutic drugs are having the desired effects on a molecular level.

Tamoxifen and raloxifene slow down the progression of muscular dystrophy
Steroids are currently the only available treatment to reduce the repetitive cycles of inflammation and disease progression associated with functional deterioration in patients with muscular dystrophy (MD).

Designed proteins to treat muscular dystrophy
The cell scaffolding holds muscle fibers together and protects them from damage.

Gene-editing alternative corrects Duchenne muscular dystrophy
Using the new gene-editing enzyme CRISPR-Cpf1, researchers at UT Southwestern Medical Center have successfully corrected Duchenne muscular dystrophy in human cells and mice in the lab.

GW researcher finds genetic cause of new type of muscular dystrophy
George Washington University & St. George's University of London research, published in The American Journal of Human Genetics, outlines a newly discovered genetic mutation associated with short stature, muscle weakness, intellectual disability, and cataracts, leading researchers to believe this is a new type of congenital muscular dystrophy.

Read More: Muscular Dystrophy News and Muscular Dystrophy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.